Skip to content
Search

Latest Stories

Atnahs acquires five drugs of Astrazeneca

The UK-based Astrazeneca said that it has decided to sell the commercial rights of five of its drugs- mainly used to treat hypertension--to Atnahs Pharma.

The business offloaded for up to $390 million as it focuses on new potential medicines to boost its market globally.


Atnahs will make an upfront payment of $350m to Astrazeneca.

Astrazeneca may also receive future sales-contingent payments of up to $40m between 2020 and 2022.

The Cambridge-based company will continue to make and supply the drugs, which include inderal and tenormin.

The divestment is expected to complete in the first quarter of 2020.

According to the deal inked, Astrazeneca has agreed to sell the global commercial rights of inderal (propranolol), tenormin (atenolol), tenoretic (atenolol, chlorthalidone fixed-dose combination), zestril (lisinopril) and zestoretic (lisinopril, hydrochlorothiazide fixed-dose combination) to Atnahs Pharma.

The agreement excludes the rights in the US and India, which were previously divested, and in Japan, which will be retained by Astrazeneca. The medicines have lost their patent protection globally.

Astrazeneca will continue to manufacture and supply inderal, tenormin, tenoretic, zestril and zestoretic to Atnahs during a transition period.

Atnahs is owned by Vijay and Bhikhu Patel of Waymade.

Astrazeneca was created through the combination of Astra of Sweden and Zeneca of Britain in 1999.

More For You

Deliveroo posts first annual profit after 12 years

A Deliveroo rider near Victoria station in London, England. (Photo by Dan Kitwood/Getty Images)

Deliveroo posts first annual profit after 12 years

FOOD DELIVERY app Deliveroo announced on Thursday (13) its first annual profit as orders and revenue rose, while the 12-year old company sees further growth despite exiting Hong Kong.

The milestone follows sizeable full-year losses owing to high investment costs since American Will Shu founded the company in 2013 and made Deliveroo's first delivery in London.

Keep ReadingShow less
JLR-Tata-Getty

JLR had initially planned to manufacture more than 70,000 electric vehicles at the facility. (Photo: Getty Images)

JLR halts plan to build EVs at Tata’s India plant: Report

JAGUAR LAND ROVER (JLR) has put on hold plans to manufacture electric vehicles at Tata Motors’ upcoming £775 million factory in southern India, according to a news report.

The decision was influenced by challenges in balancing price and quality for locally sourced EV components, three of the sources said. They added that slowing demand for electric vehicles was also a factor.

Keep ReadingShow less
Government to abolish payments regulator to boost growth

Keir Starmer (R) and Rachel Reeves host an investment roundtable discussion with members of the BlackRock executive board at 10 Downing Street on November 21, 2024 in London, England. (Photo by Frank Augstein - WPA Pool/Getty Images)

Government to abolish payments regulator to boost growth

PAYMENTS REGULATOR will be abolished and its remit absorbed by another financial regulator, the government said on Tuesday (11), as it aims to cut red tape in favour of growth.

The Payment Systems Regulator (PSR), which oversees systems including MasterCard and bank transfers, tackles problems such as fraud, excessive fees and lack of competition among banks and payment providers.

Keep ReadingShow less
Boohoo

Boohoo’s shares, which have fallen by about 20 per cent this year, dropped 4 per cent on Tuesday. (Photo: Getty Images)

Boohoo rebrands as Debenhams after 21 per cent sales drop

BOOHOO has rebranded itself as Debenhams Group after sales from its young fashion brands, including Boohoo, MAN, and PrettyLittleThing, declined by 21 per cent to £947 million.

The move comes amid strong competition from Shein and a shift towards second-hand clothing among younger shoppers, The Guardian reported.

Keep ReadingShow less